Literature DB >> 17873130

18F-FDOPA kinetics in brain tumors.

Christiaan Schiepers1, Wei Chen, Timothy Cloughesy, Magnus Dahlbom, Sung-Cheng Huang.   

Abstract

UNLABELLED: L-3,4-Dihydroxy-6-(18)F-fluoro-phenyl-alanine ((18)F-FDOPA) is an amino acid analog used to evaluate presynaptic dopaminergic neuronal function. Evaluation of tumor recurrence in neurooncology is another application. Here, the kinetics of (18)F-FDOPA in brain tumors were investigated.
METHODS: A total of 37 patients underwent 45 studies; 10 had grade IV, 10 had grade III, and 13 had grade II brain tumors; 2 had metastases; and 2 had benign lesions. After (18)F-DOPA was administered at 1.5-5 MBq/kg, dynamic PET images were acquired for 75 min. Images were reconstructed with iterative algorithms, and corrections for attenuation and scatter were applied. Images representing venous structures, the striatum, and tumors were generated with factor analysis, and from these, input and output functions were derived with simple threshold techniques. Compartmental modeling was applied to estimate rate constants.
RESULTS: A 2-compartment model was able to describe (18)F-FDOPA kinetics in tumors and the cerebellum but not the striatum. A 3-compartment model with corrections for tissue blood volume, metabolites, and partial volume appeared to be superior for describing (18)F-FDOPA kinetics in tumors and the striatum. A significant correlation was found between influx rate constant K and late uptake (standardized uptake value from 65 to 75 min), whereas the correlation of K with early uptake was weak. High-grade tumors had significantly higher transport rate constant k(1), equilibrium distribution volumes, and influx rate constant K than did low-grade tumors (P < 0.01). Tumor uptake showed a maximum at about 15 min, whereas the striatum typically showed a plateau-shaped curve. Patlak graphical analysis did not provide accurate parameter estimates. Logan graphical analysis yielded reliable estimates of the distribution volume and could separate newly diagnosed high-grade tumors from low-grade tumors.
CONCLUSION: A 2-compartment model was able to describe (18)F-FDOPA kinetics in tumors in a first approximation. A 3-compartment model with corrections for metabolites and partial volume could adequately describe (18)F-FDOPA kinetics in tumors, the striatum, and the cerebellum. This model suggests that (18)F-FDOPA was transported but not trapped in tumors, unlike in the striatum. The shape of the uptake curve appeared to be related to tumor grade. After an early maximum, high-grade tumors had a steep descending branch, whereas low-grade tumors had a slowly declining curve, like that for the cerebellum but on a higher scale.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873130     DOI: 10.2967/jnumed.106.039321

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  42 in total

1.  Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy.

Authors:  Johannes Schwarzenberg; Johannes Czernin; Timothy F Cloughesy; Benjamin M Ellingson; Whitney B Pope; Tristan Grogan; David Elashoff; Cheri Geist; Daniel H S Silverman; Michael E Phelps; Wei Chen
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

2.  Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.

Authors:  Ken Herrmann; Johannes Czernin; Timothy Cloughesy; Albert Lai; Kelsey L Pomykala; Matthias R Benz; Andreas K Buck; Michael E Phelps; Wei Chen
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 3.  Image-derived input function for brain PET studies: many challenges and few opportunities.

Authors:  Paolo Zanotti-Fregonara; Kewei Chen; Jeih-San Liow; Masahiro Fujita; Robert B Innis
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-03       Impact factor: 6.200

Review 4.  Metabolic positron emission tomography imaging in cancer detection and therapy response.

Authors:  Aizhi Zhu; Daniel Lee; Hyunsuk Shim
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 5.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

6.  A kinetic solution for the paradoxical difference between F-Dopa and methionine.

Authors:  Masashi Kameyama; Yumi Umeda-Kameyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-12       Impact factor: 9.236

7.  Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma.

Authors:  Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Andrea Schaefer; Georgios Farmakis; Aleksandar Grgic; Jean R Moringlane; Wolf-Ingo Steudel; Carl-Martin Kirsch; Samuel Samnick
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-30       Impact factor: 9.236

Review 8.  Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma.

Authors:  Peter M Clark; Wilson X Mai; Timothy F Cloughesy; David A Nathanson
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

9.  18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.

Authors:  Sellam Karunanithi; Punit Sharma; Abhishek Kumar; Bangkim Chandra Khangembam; Guru Pada Bandopadhyaya; Rakesh Kumar; Deepak Kumar Gupta; Arun Malhotra; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-23       Impact factor: 9.236

10.  Correlation of MRI-derived apparent diffusion coefficients in newly diagnosed gliomas with [18F]-fluoro-L-dopa PET: what are we really measuring with minimum ADC?

Authors:  S Rose; M Fay; P Thomas; P Bourgeat; N Dowson; O Salvado; Y Gal; A Coulthard; S Crozier
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-18       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.